2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / KT&G Corp, Abliva  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
2-isopropyl-3H-naphtho[2,1-d]imidazole-4,5-dione (KL1333) / Abliva, KT&G Corp
KL1333 2018-102, NCT03888716: A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

Completed
1a/1b
72
Europe
KL1333, Placebo Oral Tablet
Abliva AB
Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
03/21
03/21
NCT03056209: Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

Completed
1
60
RoW
KL1333 25 mg, KL1333 50 mg, KL1333 100 mg, KL1333 200 mg, KL1333 400 mg, KL1333 600 mg, KL1333 800 mg, Placebo
Yungjin Pharm. Co., Ltd.
MELAS Syndrome, Mitochondrial Respiratory Chain Deficiencies
04/18
04/18
KL1333 2020-103, NCT04643249: Drug-drug Interaction Study of KL1333 in Healthy Subjects

Completed
1
14
Europe
KL1333, Flurbiprofen, Dextromethorphan, Bupropion, Midazolam injection, Midazolam, Omeprazole, Caffeine, Repaglinide
Abliva AB
Mitochondrial Disease
12/20
12/20

Download Options